Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure
Abstract
BACKGROUND: The Asian Working Group for Sarcopenia (AWGS) updated its diagnostic criteria in 2025 by incorporating body mass index (BMI)-adjusted skeletal muscle mass. This revision may influence the prevalence and clinical interpretation of sarcopenic obesity in heart failure (HF). METHODS AND RESULTS: We conducted a single-center retrospective cohort study of 589 patients aged ≥65 years who were hospitalized for HF. Application of the AWGS 2025 criteria significantly altered classification, increasing the prevalence of sarcopenic obesity from 7.8% to 13.6%. Among the 4 groups defined by sarcopenia (AWGS 2025) and obesity, patients with sarcopenia without obesity had the worst prognosis, whereas those with sarcopenic obesity had preserved survival (log-rank P=0.038). Following the transition from the AWGS 2019 to AWGS 2025 criteria, newly classified patients with sarcopenic obesity were more frequently female and had a higher BMI with preserved height-adjusted muscle mass compared with patients with persistent sarcopenic obesity. Mortality and gait speed were comparable between the persistent and newly classified sarcopenic obesity groups (both P>0.05). The AWGS 2025 sarcopenia-obesity phenotype classification showed no improvement in discrimination or the Akaike information criterion for prognosis compared with the AWGS 2019 classification (both P>0.05). CONCLUSIONS: The AWGS 2025 criteria increase the prevalence of sarcopenic obesity by identifying a distinct phenotype in patients with HF. However, this expanded classification does not improve risk stratification.
Related
- Prevalence and clinical characterization of malnutrition, sarcopenia and sarcopenic obesity in older adults with cardiometabolic diseases: SENIOR cross-sectional study
- Prevalence of Sarcopenia in Korean Adults Based on the Asian Working Group for Sarcopenia 2025 Criteria: Analysis of the 2024 Korea National Health and Nutrition Examination Survey
- Changing sarcopenia diagnostic criteria from AWGS2019 to 2025 impacts prevalence and postoperative risk prediction
- Defining Sarcopenic Obesity in the Asian Working Group for Sarcopenia 2025 Era: Diagnostic Precision Matters
- Urinary organophosphate flame retardants and risk of sarcopenia and sarcopenic obesity among middle-aged and older adults: a systematic investigation integrating epidemiological and adverse outcome pathway analyses
BibTeX
@article{ozaki2026impact,
title = {{Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure}},
author = {Yuta Ozaki and Yusuke Uemura and Shigefumi Honda and Toru Kondo and Shingo Kazama and Kenji Takemoto and Masato Watarai},
journal = {Circulation Journal},
year = {2026},
month = oct,
doi = {10.1253/circj.cj-26-0440},
url = {https://www.jstage.jst.go.jp/article/circj/90/11/90_CJ-26-0440/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure
AU - Yuta Ozaki
AU - Yusuke Uemura
AU - Shigefumi Honda
AU - Toru Kondo
AU - Shingo Kazama
AU - Kenji Takemoto
AU - Masato Watarai
PY - 2026
DA - 2026/10/23
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0440
UR - https://www.jstage.jst.go.jp/article/circj/90/11/90_CJ-26-0440/_article
AB - BACKGROUND: The Asian Working Group for Sarcopenia (AWGS) updated its diagnostic criteria in 2025 by incorporating body mass index (BMI)-adjusted skeletal muscle mass. This revision may influence the prevalence and clinical interpretation of sarcopenic obesity in heart failure (HF). METHODS AND RESULTS: We conducted a single-center retrospective cohort study of 589 patients aged ≥65 years who were hospitalized for HF. Application of the AWGS 2025 criteria significantly altered classification, increasing the prevalence of sarcopenic obesity from 7.8% to 13.6%. Among the 4 groups defined by sarcopenia (AWGS 2025) and obesity, patients with sarcopenia without obesity had the worst prognosis, whereas those with sarcopenic obesity had preserved survival (log-rank P=0.038). Following the transition from the AWGS 2019 to AWGS 2025 criteria, newly classified patients with sarcopenic obesity were more frequently female and had a higher BMI with preserved height-adjusted muscle mass compared with patients with persistent sarcopenic obesity. Mortality and gait speed were comparable between the persistent and newly classified sarcopenic obesity groups (both P>0.05). The AWGS 2025 sarcopenia-obesity phenotype classification showed no improvement in discrimination or the Akaike information criterion for prognosis compared with the AWGS 2019 classification (both P>0.05). CONCLUSIONS: The AWGS 2025 criteria increase the prevalence of sarcopenic obesity by identifying a distinct phenotype in patients with HF. However, this expanded classification does not improve risk stratification.
SN - 1347-4820
SN - 1346-9843
ER -